These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Therapeutic targeting of c-KIT in cancer. Ashman LK; Griffith R Expert Opin Investig Drugs; 2013 Jan; 22(1):103-15. PubMed ID: 23127174 [TBL] [Abstract][Full Text] [Related]
43. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
44. Gastrointestinal stromal tumors. Antonescu C Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552 [TBL] [Abstract][Full Text] [Related]
45. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500 [TBL] [Abstract][Full Text] [Related]
46. MicroRNAs and Gastrointestinal Stromal Tumor. Akçakaya P; Lui WO Adv Exp Med Biol; 2015; 889():51-70. PubMed ID: 26658996 [TBL] [Abstract][Full Text] [Related]
47. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- Wu Y; Wang B; Wang J; Qi S; Zou F; Qi Z; Liu F; Liu Q; Chen C; Hu C; Hu Z; Wang A; Wang L; Wang W; Ren T; Cai Y; Bai M; Liu Q; Liu J J Med Chem; 2019 Jul; 62(13):6083-6101. PubMed ID: 31250638 [TBL] [Abstract][Full Text] [Related]
48. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767 [TBL] [Abstract][Full Text] [Related]
49. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor. Zheng S; Pan YL; Tao DY; Wang JL; Huang KE Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980 [TBL] [Abstract][Full Text] [Related]
50. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. Montemurro M; Bauer S Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258 [TBL] [Abstract][Full Text] [Related]
51. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). Nannini M; Biasco G; Astolfi A; Pantaleo MA J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252 [TBL] [Abstract][Full Text] [Related]
52. KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions. Fletcher JA Cancer Res; 2016 Nov; 76(21):6140-6142. PubMed ID: 27803101 [No Abstract] [Full Text] [Related]
53. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512 [TBL] [Abstract][Full Text] [Related]
54. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Roskoski R Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617 [TBL] [Abstract][Full Text] [Related]
55. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors. Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309 [TBL] [Abstract][Full Text] [Related]
56. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors]. Xu J; Cao H Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353 [TBL] [Abstract][Full Text] [Related]
57. miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Nannini M; Ravegnini G; Angelini S; Astolfi A; Biasco G; Pantaleo MA Epigenomics; 2015; 7(6):1033-49. PubMed ID: 26447534 [TBL] [Abstract][Full Text] [Related]
59. Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors. Kettle JG; Anjum R; Barry E; Bhavsar D; Brown C; Boyd S; Campbell A; Goldberg K; Grondine M; Guichard S; Hardy CJ; Hunt T; Jones RDO; Li X; Moleva O; Ogg D; Overman RC; Packer MJ; Pearson S; Schimpl M; Shao W; Smith A; Smith JM; Stead D; Stokes S; Tucker M; Ye Y J Med Chem; 2018 Oct; 61(19):8797-8810. PubMed ID: 30204441 [TBL] [Abstract][Full Text] [Related]
60. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance. Srikakulam SK; Bastys T; Kalinina OV Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]